Viatris management check

VTRS · Health Care · Pharmaceuticals · CEO Scott A. Smith

Filings as of

57
Management score, ranked 369th of 487Strongest: dilution. Weakest: owner returns. See the best and worst run in Health Care →

1 good · 3 to watch · 1 flagged, across the seven questions below.

  • Flag

    Have owners done well?

    Trailed its chosen peers

    $100 invested at the start of fiscal 2021 grew to $81, against $186 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.63 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • n/a

    What does the CEO cost owners?

    Not enough data

    No pay or net income figure for the latest year.

  • n/a

    Do they own the stock?

    No recent CEO filing

    Light activity: no buys, $810k sold in six months. 1 of 1 sales ran on pre-arranged 10b5-1 plans.

  • Watch

    Are owners being diluted?

    Stock pay 1.2% of revenue

    Stock-based pay was 1.2% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    CEOs in the pay table: Michael Goettler, Scott A. Smith. 9 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Watch

    Are the books clean?

    An annual report was amended

    No restatements, auditor changes or late filings since 2021. 4 amended annual reports.

Against the S&P 500

Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.

CheckScoreAt or aboveSector median
Owner returns016%26
Pay for performance8147%85
CEO cost——44
Skin in the game——46
Dilution9281%68
Stable leadership4019%70
Clean books7014%100

Closest peers

Others in Pharmaceuticals, by management score. Viatris is 45th of 60 in its sector.

  1. 32LLYLilly (Eli)84
  2. 181ZTSZoetis70
  3. 190JNJJohnson & Johnson69
  4. 207BMYBristol Myers Squibb68
  5. 263PFEPfizer64
  6. 323MRKMerck & Co.60
  7. 369VTRSViatris57

Pay versus performance

From the proxy statement filed April 2, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.

CEO pay by fiscal yearAs reported Actually paid
$0$12.4m$24.7m20212022202320242025
What $100 becameCompany Peer group
$10020212022202320242025$81
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Scott A. Smith$15.3m$24.7m$5.2m$81$186—
2024Scott A. Smith$14.8m$17.8m$5.5m$77$145—
2023Michael Goettler, Scott A. Smith$15.9m$17.8m$14.3m$65$135—
2022Michael Goettler$14.8m$14.3m$14.9m$63$135—
2021Michael Goettler$14.8m$13.6m$10.5m$74$125—

The board says pay is tied most to Free Cash Flow. Its other key measures: Adjusted EBITDA, Relative TSR.

Insiders and the CEO's stake

Light activity: no buys, $810k sold in six months. 1 of 1 sales ran on pre-arranged 10b5-1 plans.

  • SoldPaul CampbellSee Remarks · 10b5-1 plan$810kJun 25, 2026

Leadership and governance on file

Latest shareholder vote results: May 15, 2026, including the say-on-pay vote.

Where the money went

Over 2021–2025: $1.0bn returned to owners in buybacks and dividends, and $732.1m of pay in stock.

Fiscal year20212022202320242025
Revenue$17.8bn$16.2bn$15.4bn$14.7bn$14.3bn
Net income—————
Stock-based pay$111.2m$116.4m$180.7m$146.1m$177.7m
Buybacks$0$0$250.0m$250.0m$500.5m
Dividends—————
Diluted shares1209m1217m1207m——

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.